In recent months, the Chinese Foreign Affairs Ministry and Shi Zhengli, the WIV virologist nicknamed "Bat Woman" for her research on coronaviruses of bat origin, denied there is a connection between the WIV and military, and said that no WIV researchers were infected with COVID-19.
According to an investigation conducted by the U.S. State Department, "Several researchers inside the WIV became sick in autumn 2019, before the first identified case of the outbreak, with symptoms consistent with both COVID-19 and common seasonal illnesses." "The WIV has engaged in classified research, including laboratory animal experiments, on behalf of the Chinese military since at least 2017," states a State Department fact sheet.
Shi didn't mention that the WIV was used by a Chinese military medical team in early 2020 for developing COVID-19 vaccines.
The magazine reported that according to Shi, "There is 'zero infection' among staff or students with SARS-CoV-2 or SARS-related viruses." In late March, overseas Chinese media reported that three WIV staff members started to have symptoms similar to COVID-19 as early as November 2019.
China News reported that a Chinese specialist told the WHO investigation team-which visited China in February to investigate the origin of the CCP virus-that cases dating back to 2019 were patients at WIV-related hospitals, rather than members of WIV staff.
On Jan. 26, 2020, Cao accompanied Chen to Wuhan and they took over command of the WIV. Chinese state-run media reported, at that time, that the main purpose of the military take-over was to develop a vaccine against the CCP virus.
On July 15, 2020, virologist Jonathan Latham and molecular biologist Allison Wilson from Ithaca, N.Y., co-published an article in Independent Science News after translating a 66-page master's thesis by Li Xu, a Chinese medical doctor who treated the miners and sent their tissue samples to the WIV for testing.
Tuesday, May 4, 2021
Evidence Reveals That Military Team Collaborated With Lab Where COVID-19 Pandemic Originated
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment